From Product to Global Profitability in Horses

We completed our “roadmap to EMA & FDA / USDA approvals”, are prepared for global launches in few years and have presented at leading investor conferences in 2025 attracting good interest and resonance by investors

Dual mechanism of action, vaccination and intra cellular stimulation for cell death

Impressive CR/R and “cure” results

CMC and pivotal studies (II-III) good to go

Focus on clinical & commercialisation

“When the strategy is clear, execution becomes the new strategy”

P. Drucker (1965)

Our product is prepared for clinical confirmation after 29 & 48+ horses (77+) successfully treated on sarcoids (skin cancers) including many most severe cases in late stage (pre-bone metastasis)

As part of EDC companies, we were selected and developed by NEMOO AI Value Builders EDC AG. We continue to benefit from their support and coaching, their structure, networks and governance. We jointly develop our projects, people, teams, ultimately products and simple AI solutions for doctors. We also sit together for future growth options to expand (vaccines, other animals)

Our team is very solid, science, development, launches and finance

We want to partner with investors to create far more value together

From Product to Profitability

The core team consists of various skills, backgrounds, operational and leadership experiences in drug development (PAREXEL), manufacturing (LONZA), biotech and pharma commercial (AstraZeneca), scientific and clinical development (BlueSky), regulatory and corporate finance in pharma (SP/Merck) & biotechnology (BlueSky)

Advisor IA
(ex SP/MSD,
Switzerland, USA)
Advisor IA
(ex Amgen IP & Legal
Head EMEA, Switzerland)
Advisor IA
(Prof. of Kellogg MBA, Germany, Sweden)
Advisor IA
(ex MSD, Novartis, Swiss Investment Banking)

We are posting updates and relevant news from time to time on the development of our products in horses and camels and our company